MPC-3100

MPC-3100

CAT N°: 22496
Price:

From 122.00 103.70

MPC-3100 is an inhibitor of heat shock protein 90 (Hsp90; IC50 = 0.14 µM in a fluorescence polarization assay).{53052} It inhibits proliferation of a variety of cancer cell lines, including colon, prostate, ovarian, gastric, and breast cancer cells (IC50s = 0.2-0.55 µM), as well as MV4-11 leukemia, A549 non-small cell lung cancer (NSCLC), NCI H69 SCLC, and multidrug-resistant NCI/ADR-RES cells (IC50s = 0.25, 0.77, 0.15, and 4.3 µM, respectively). MPC-3100 induces degradation of the Hsp90 client proteins Akt and HER2 (IC50s = 0.1-0.5 µM) and a compensatory Hsp70 response in NCI N87, HCT116, and DU145 cell lysates. It also induces Hsp70 expression in the liver and tumor tissue and reduces tumor growth in an NCI N87 mouse xenograft model when administered at doses of 50 and 75 mg/kg. It induces tumor regression in the same model when administered at doses of 125 and 200 mg/kg.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • (2S)-1-[4-[2-[6-amino-8-[(6-bromo-1,3-benzodioxol-5-yl)thio]-9H-purin-9-yl]ethyl]-1-piperidinyl]-2-hydroxy-1-propanone
  • Correlated keywords
    • MPC300 Hsp-90 70 MV-411 MV411 A-549 NCIH69 NCIN87 H-69 N-87 HCT-116 DU-145 HER-2
  • Product Overview:
    MPC-3100 is an inhibitor of heat shock protein 90 (Hsp90; IC50 = 0.14 µM in a fluorescence polarization assay).{53052} It inhibits proliferation of a variety of cancer cell lines, including colon, prostate, ovarian, gastric, and breast cancer cells (IC50s = 0.2-0.55 µM), as well as MV4-11 leukemia, A549 non-small cell lung cancer (NSCLC), NCI H69 SCLC, and multidrug-resistant NCI/ADR-RES cells (IC50s = 0.25, 0.77, 0.15, and 4.3 µM, respectively). MPC-3100 induces degradation of the Hsp90 client proteins Akt and HER2 (IC50s = 0.1-0.5 µM) and a compensatory Hsp70 response in NCI N87, HCT116, and DU145 cell lysates. It also induces Hsp70 expression in the liver and tumor tissue and reduces tumor growth in an NCI N87 mouse xenograft model when administered at doses of 50 and 75 mg/kg. It induces tumor regression in the same model when administered at doses of 125 and 200 mg/kg.

We also advise you